PDL BioPharma, Inc. (NASDAQ:PDLI) will release the third quarter earnings for 2009 on Tuesday, October 27. The financial results will be posted as a press release on the company’s website, www.pdlbiopharma.com, on the News Releases page of the Investors section.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
PDL BioPharma, Inc. (PDL) is engaged in the business of management of its antibody humanization patents and royalty assets, which consist of the Company’s Queen et al. patents and license agreements with several biotechnology and pharmaceutical companies. The Company receives royalties based on these license agreements on sales of a number of humanized antibody products marketed, and also receives royalty payments on additional humanized antibody products. The Company receives royalties on sales of nine humanized antibody products, which include Avastin, Herceptin, Xolair, Raptiva, Lucentis, Synagis, Tysabri, Mylotarg and Actemra. In March 2008, PDL completed the divestiture of its commercial and manufacturing operations. On December 17, 2008, the Company transferred its biotechnology operations to Facet Biotech Corporation (Facet).
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
